{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:46:59Z","timestamp":1785034019631,"version":"3.55.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>The presence of epithelial-mesenchymal transition (EMT) in breast cancer (BC) cells has been linked to worse prognosis and may influence response to systemic treatment. We explored the effect of EMT in tumor samples of patients with metastatic BC on disease-free interval and overall survival in those patients receiving eribulin or cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>\n              Key inclusion criteria included available archived primary BC tissue and, where available, matched metastatic biopsy. Patients received eribulin and\/or a CDK4\/6i in the metastatic setting. Specimens were assessed for biomarkers by immunohistochemistry (CDH1, AE1\/3, VIM, CDH2, ZEB1, pSMAD2, and SMAD4) and gene expression by droplet digital polymerase chain reaction (\n              <jats:italic>CDH1<\/jats:italic>\n              ,\n              <jats:italic>CDH2<\/jats:italic>\n              ,\n              <jats:italic>SNAI1<\/jats:italic>\n              &amp;\n              <jats:italic>2<\/jats:italic>\n              ,\n              <jats:italic>TWIST1<\/jats:italic>\n              ,\n              <jats:italic>VIM<\/jats:italic>\n              ,\n              <jats:italic>PTEN<\/jats:italic>\n              , and\n              <jats:italic>ZEB1<\/jats:italic>\n              &amp;\n              <jats:italic>2<\/jats:italic>\n              ).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Between 2002 and 2020, 127 patients were included (95 early-stage disease at diagnosis with metastatic relapse, 32 de novo metastatic disease). In metastatic samples, presence of ZEB1 overexpression was associated with shorter time to recurrence (48.1 months shorter;\n              <jats:italic>P<\/jats:italic>\n              = .003), with pSMAD2 overexpression suggesting clinical significance of 52.0 months shorter;\n              <jats:italic>P<\/jats:italic>\n              = .01. High gene expression levels for SNAIL1,\n              <jats:italic>TWIST1<\/jats:italic>\n              , and\n              <jats:italic>PTEN<\/jats:italic>\n              in the primary BC were associated with significantly longer survival in patients who received eribulin (\n              <jats:italic>P<\/jats:italic>\n              &lt; .05); high\n              <jats:italic>VIM<\/jats:italic>\n              was associated with a clinically relevant trend toward shorter survival after a CDK4\/6i (\n              <jats:italic>P<\/jats:italic>\n              = .013).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>We demonstrate in our exploratory study that biomarkers involved in the process of EMT could have a prognostic impact in a cohort of patients with BC uniformly treated and with long-term follow-up. Genes known to be involved in EMT were associated with improved eribulin efficacy, while suggesting a poorer outcome with CDK4\/6i.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po.24.00274","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T20:59:59Z","timestamp":1733518799000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":4,"title":["Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-2286","authenticated-orcid":true,"given":"Arlene","family":"Chan","sequence":"first","affiliation":[{"name":"Breast Cancer Research Centre-WA and Curtin University, Perth, Australia"},{"name":"Curtin Medical School, Curtin University, Bentley, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jespal","family":"Gill","sequence":"additional","affiliation":[{"name":"Anatomical Pathology, Western Diagnostics, Jandakot and PathWest, Murdoch, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9294-0996","authenticated-orcid":true,"given":"HuiJun","family":"Chih","sequence":"additional","affiliation":[{"name":"School of Population Health, Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-6677","authenticated-orcid":true,"given":"Sarah Christine Elisabeth","family":"Wright","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Bentley, Australia"},{"name":"Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-7937","authenticated-orcid":true,"given":"Natali","family":"Vasilevski","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Bentley, Australia"},{"name":"Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5840-943X","authenticated-orcid":true,"given":"Pieter Johan Adam","family":"Eichhorn","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Bentley, Australia"},{"name":"Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05838-7"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2938"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2023.10.004"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.215"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.26"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0345"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi901810u"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106131"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5020017"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0562"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-2946-1"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2015.18.3.256"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.11.001"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3758"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315215"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S149801"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.010"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.07.026"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3251-9"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds333"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kww015"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29723-5"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5070065"},{"key":"e_1_3_5_29_2","first-page":"2929","article-title":"Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer","volume":"38","author":"Goto W","year":"2018","unstructured":"Goto W, Kashiwagi S, Asano Y, et al: Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer. Anticancer Res 38:2929-2938, 2018","journal-title":"Anticancer Res"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215388"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00840-4"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0728"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1148792"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(19)31118-X"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.24.00274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:00:05Z","timestamp":1733518805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.24.00274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1200\/PO.24.00274"],"URL":"https:\/\/doi.org\/10.1200\/po.24.00274","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400274"}}